SCHEMBL18501604

SCHEMBL18501604

CC(C)(C)NCCCCC(CO)COC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25671080 0.78 TDP1 (0.40) POLBTDP1
SCHEMBL25671162 0.78 TDP1 (0.40) POLBTDP1
SCHEMBL22995685 0.77 MAPK1 (0.38) MAPK1LMNA
SCHEMBL25671082 0.77 TDP1 (0.36) TDP1
SCHEMBL18501606 0.77 TDP1 (0.36) TDP1
SCHEMBL17471306 0.73 MAPK1 (0.52) MAPK1
SCHEMBL21104000 0.72 CAPN1 (0.33) TDP1
SCHEMBL21103841 0.70 ALDH1A1 (0.37) POLBTDP1
SCHEMBL21089991 0.69 POLB (0.31) POLB
SCHEMBL22373733 0.69 HRH4 (0.34) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753638-B2 Conjugated oligonucleotides UNIVERSITY OF MASSACHUSETTS (US) 2023-09-12 US disclosed
US-11753638-B2 Conjugated oligonucleotides UNIVERSITY OF MASSACHUSETTS (US) 2023-09-12 US disclosed
US-20200339983-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2020-10-29 US disclosed
US-20190185855-A1 CONJUGATED OLIGONUCLEOTIDES UNIVERSITY OF MASSACHUSETTS 2019-06-20 US disclosed
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2017-02-16 US disclosed
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753638-B2 Conjugated oligonucleotides DCLRE1B, DCLRE1A, TNNC1 MAPK1 4848/4885LMNA 3065/4885POLB 32/4885
US-20200339983-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY DCLRE1B, RTCB, RNASE1 MAPK1 4396/4885LMNA 1428/4885POLB 440/4885
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY DCLRE1B, RTCB, RNASE1 MAPK1 4396/4885LMNA 1428/4885POLB 440/4885
US-20190185855-A1 CONJUGATED OLIGONUCLEOTIDES DCLRE1B, DCLRE1A, TNNC1 MAPK1 4848/4885LMNA 3065/4885POLB 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.